Tempus AI’s IPS Test Outperforms Conventional Biomarkers in Predicting Immunotherapy Outcomes

Tempus AI announced on January 27, 2026, that its AI-driven Immune Profile Score (IPS) test more accurately predicts outcomes for patients on immune checkpoint inhibitors (ICIs) than conventional biomarkers like TMB, MSI, and PD-L11 2 3

IPS, a multimodal biomarker using DNA and RNA data, showed HR=0.45 in four pan-cancer cohorts, independent of traditional markers1

IPS identified 13% of microsatellite stable colorectal cancer patients with strong ICI survival (HR=0.2), expanding options for overlooked groups1 2

For rare metastatic solid tumors, 17% classified as IPS-High showed better survival (HR=0.26), despite not fitting FDA labels1 2

IPS is available as an add-on to Tempus' xT (DNA) and xR (RNA) assays1

Halla Nimeiri, Tempus Chief Development Officer, stated IPS advances personalized cancer care1 2

Sources:

1. https://www.tempus.com/news/tempus-reveals-its-ai-driven-ips-test-more-accurately-predicts-immunotherapy-benefit-compared-to-conventional-biomarkers/

2. https://www.investing.com/news/company-news/tempus-ai-study-shows-improved-cancer-immunotherapy-prediction-93CH-4467561

3. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/tempus-ai-ips-study-points-to-wider-immunotherapy-use-and-in

Sources:

Leave a Reply Cancel reply